search
Back to results

Oral Huzhang Granules for Acute Gouty Arthritis

Primary Purpose

Gouty Arthritis

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Huzhang granule
Etoricoxib
Huzhang granule Placebo
Etoricoxib Placebo
Sponsored by
Shanghai Yueyang Integrated Medicine Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gouty Arthritis focused on measuring Gouty arthritis, Randomized controlled trial, Huzhang granule, Traditional Chinese medicine

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of acute gout arthritis as defined by the American College of Rheumatology 1977 preliminary criteria;
  • Male or non-pregnant, non-nursing female;
  • 18-70 years of age;
  • Gout attack less ≤48 hours;
  • In the week before this observation, non-steroidal anti-inflammatory drugs and analgesic drugs and drugs affecting uric acid metabolism were not taken;
  • Subjects capable of giving informed consent;

Exclusion Criteria:

  • failing to meet the diagnostic criteria;
  • Evidence of uncontrolled concomitant cardiovascular, nervous system,hepatic or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after discussion and agreement with the treating medical team;
  • the patient is in critical condition and it is difficult to evaluate the effectiveness and safety of the clinical observation;
  • severe deformity, stiffness and labor loss of patients with advanced arthritis;
  • known allergic to the drug used in this study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Placebo Comparator

    Arm Label

    HZG intervention

    Etoricoxib intervention

    Placebo intervention

    Arm Description

    During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.

    During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.

    During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.

    Outcomes

    Primary Outcome Measures

    Visual Analogue Score (VAS)
    Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack,it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain)

    Secondary Outcome Measures

    Likert scales for the assessment of joint tenderness and swelling
    Likert scales for the assessment of joint tenderness and swelling is evaluate the inflammatory response and the degree of injury of the joint.Scores range from 1-5, a higher score indicating a severe symptoms on a participant's joint
    symptom relief time
    Symptom relief time is the time when joint pain feels relieved
    36-Item Short Form Survey
    36-Item Short Form Survey is a health status profile originally designed to measure eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Scoring the 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key in a given table. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. another lists the items averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating

    Full Information

    First Posted
    June 30, 2020
    Last Updated
    July 5, 2020
    Sponsor
    Shanghai Yueyang Integrated Medicine Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04462666
    Brief Title
    Oral Huzhang Granules for Acute Gouty Arthritis
    Official Title
    Oral Huzhang Granules for Acute Gouty Arthritis: Protocol for a Randomized, Double-blind, Multicenter Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 1, 2020 (Anticipated)
    Primary Completion Date
    July 31, 2023 (Anticipated)
    Study Completion Date
    August 31, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Shanghai Yueyang Integrated Medicine Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    We designed this study as a double-blind, randomized, controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of acute gouty arthritis
    Detailed Description
    Gout is a recurrent chronic inflammatory disease caused by monosodium urate (MSU) crystal . Acute gouty arthritis (GA) is the most common first symptom of gout. With the progress of the disease, the frequency of acute attack increases, and joint destruction may occur. The prevalence of hyperuricemia in China was about 13.3%, and the pooled prevalence of gout was 1.1%. Repeated attacks of GA seriously affect the quality of life, resulting in huge economic costs and mental stress. Due to inadequate prevention and treatment, the target of healing gout is often not achieved. In GA, TCM has shown satisfactory therapeutic effect with less adverse effects and minimal toxicity. Huzhang granule (HZG), a Chinese herbal prescription, is a compound preparation with twelve ingredients which has been used in the clinical treatment of gout for over 30 years at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of TCM.Therefore,this double-blind, randomized, controlled clinical trial. will provide high-quality clinical evidences for evaluating the clinical efficacy, safety and control of recurrence rate of Huzhang granule ,a representative prescription for the treatment of acute gouty arthritis , in the treatment of GA.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gouty Arthritis
    Keywords
    Gouty arthritis, Randomized controlled trial, Huzhang granule, Traditional Chinese medicine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    267 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    HZG intervention
    Arm Type
    Experimental
    Arm Description
    During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.
    Arm Title
    Etoricoxib intervention
    Arm Type
    Active Comparator
    Arm Description
    During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.
    Arm Title
    Placebo intervention
    Arm Type
    Placebo Comparator
    Arm Description
    During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.
    Intervention Type
    Drug
    Intervention Name(s)
    Huzhang granule
    Other Intervention Name(s)
    Chinese Herbal Medicine
    Intervention Description
    Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
    Intervention Type
    Drug
    Intervention Name(s)
    Etoricoxib
    Other Intervention Name(s)
    Chemical drug
    Intervention Description
    take one capsule per day in the morning, at approximately 30 minutes after the meal.
    Intervention Type
    Drug
    Intervention Name(s)
    Huzhang granule Placebo
    Other Intervention Name(s)
    Chinese Herbal Medicine
    Intervention Description
    Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
    Intervention Type
    Drug
    Intervention Name(s)
    Etoricoxib Placebo
    Other Intervention Name(s)
    Chemical drug
    Intervention Description
    take one capsule per day in the morning, at approximately 30 minutes after the meal.
    Primary Outcome Measure Information:
    Title
    Visual Analogue Score (VAS)
    Description
    Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack,it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain)
    Time Frame
    Up to 5 days after treatment
    Secondary Outcome Measure Information:
    Title
    Likert scales for the assessment of joint tenderness and swelling
    Description
    Likert scales for the assessment of joint tenderness and swelling is evaluate the inflammatory response and the degree of injury of the joint.Scores range from 1-5, a higher score indicating a severe symptoms on a participant's joint
    Time Frame
    Up to 5 days after treatment
    Title
    symptom relief time
    Description
    Symptom relief time is the time when joint pain feels relieved
    Time Frame
    Up to 5 days after treatment
    Title
    36-Item Short Form Survey
    Description
    36-Item Short Form Survey is a health status profile originally designed to measure eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Scoring the 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key in a given table. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. another lists the items averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating
    Time Frame
    Up to 5 days after treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of acute gout arthritis as defined by the American College of Rheumatology 1977 preliminary criteria; Male or non-pregnant, non-nursing female; 18-70 years of age; Gout attack less ≤48 hours; In the week before this observation, non-steroidal anti-inflammatory drugs and analgesic drugs and drugs affecting uric acid metabolism were not taken; Subjects capable of giving informed consent; Exclusion Criteria: failing to meet the diagnostic criteria; Evidence of uncontrolled concomitant cardiovascular, nervous system,hepatic or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after discussion and agreement with the treating medical team; the patient is in critical condition and it is difficult to evaluate the effectiveness and safety of the clinical observation; severe deformity, stiffness and labor loss of patients with advanced arthritis; known allergic to the drug used in this study.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Bin Li
    Phone
    0086-021-55981301
    Email
    18930568129@163.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mi Zhou
    Phone
    0086-13636686022
    Email
    vieky2866@163.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jia Zhou
    Organizational Affiliation
    Shanghai Yueyang Integrated Medicine Hospital, Shanghai
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    35365187
    Citation
    Zhou M, Hua L, Wang YF, Chen ST, Yang CM, Zhang M, Li X, Li B. Oral Huzhang granules for the treatment of acute gouty arthritis: protocol for a double-blind, randomized, controlled trial. Trials. 2022 Apr 1;23(1):248. doi: 10.1186/s13063-022-06188-x.
    Results Reference
    derived

    Learn more about this trial

    Oral Huzhang Granules for Acute Gouty Arthritis

    We'll reach out to this number within 24 hrs